RESUMEN
Although Varicella or chickenpox infection which is caused by the varicella-zoster virus (VZV) has significantly been managed through vaccination, it remains an infection that poses threats to the nearest future due to therapeutic drawbacks. The focus of this research was geared towards in silico screening for the identification of novel compounds in plants of ethnopharmacological relevance in the treatment of chicken pox in West Africa. The work evaluated 65 compounds reported to be present in Achillea millefolium, Psidium guajava and Vitex doniana sweet to identify potential inhibitors of thymidine kinase, the primary drug target of varicella zoster virus. Out of the 65 compounds docked, 42 of these compounds were observed to possess binding energies lower than -7.0 kcal/mol, however only 20 were observed to form hydrogen bond interactions with the protein. These interactions were elucidated using LigPlot+ and MM-PBSA analysis with residue Ala134 predicted as critical for binding. Pharmacological profiling predicted three potential lead compounds comprising myricetin, apigenin- 4' -glucoside and Abyssinone V to possess good pharmacodynamics properties and negligibly toxic. The molecules were predicted as antivirals including anti-herpes and involved in mechanisms comprising inhibition of polymerase, ATPase and membrane integrity, which were corroborated previously in other viruses. These drug-like compounds are plausible biotherapeutic moieties for further biochemical and cell-based assaying to discover their potential for use against chickenpox. Communicated by Ramaswamy H. Sarma.
Asunto(s)
Antivirales , Herpesvirus Humano 3 , Fitoquímicos , Timidina Quinasa , Humanos , Antivirales/farmacología , Varicela/tratamiento farmacológico , Varicela/prevención & control , Herpes Zóster/tratamiento farmacológico , Herpes Zóster/prevención & control , Herpesvirus Humano 3/efectos de los fármacos , Timidina Quinasa/antagonistas & inhibidores , Etnofarmacología , Fitoquímicos/farmacologíaRESUMEN
OBJECTIVES: Comprehensive cost-effectiveness analyses of introducing varicella and/or herpes zoster vaccination in the Swedish national vaccination programme. DESIGN: Cost-effectiveness analyses based on epidemiological results from a specifically developed transmission model. SETTING: National vaccination programme in Sweden, over an 85- or 20-year time horizon depending on the vaccination strategy. PARTICIPANTS: Hypothetical cohorts of people aged 12 months and 65-years at baseline. INTERVENTIONS: Four alternative vaccination strategies; 1, not to vaccinate; 2, varicella vaccination with one dose of the live attenuated vaccine at age 12 months and a second dose at age 18 months; 3, herpes zoster vaccination with one dose of the live attenuated vaccine at 65 years of age; and 4, both vaccine against varicella and herpes zoster with the before-mentioned strategies. MAIN OUTCOME MEASURES: Accumulated cost and quality-adjusted life years (QALY) for each strategy, and incremental cost-effectiveness ratios (ICER). RESULTS: It would be cost-effective to vaccinate against varicella (dominant), but not to vaccinate against herpes zoster (ICER of EUR 200,000), assuming a cost-effectiveness threshold of EUR 50,000 per QALY. The incremental analysis between varicella vaccination only and the combined programme results in a cost per gained QALY of almost EUR 1.6 million. CONCLUSIONS: The results from this study are central components for policy-relevant decision-making, and suggest that it was cost-effective to introduce varicella vaccination in Sweden, whereas herpes zoster vaccination with the live attenuated vaccine for the elderly was not cost-effective-the health effects of the latter vaccination cannot be considered reasonable in relation to its costs. Future observational and surveillance studies are needed to make reasonable predictions on how boosting affects the herpes zoster incidence in the population, and thus the cost-effectiveness of a vaccination programme against varicella. Also, the link between herpes zoster and sequelae need to be studied in more detail to include it suitably in health economic evaluations.
Asunto(s)
Vacuna contra la Varicela/administración & dosificación , Varicela/prevención & control , Vacuna contra el Herpes Zóster/administración & dosificación , Herpes Zóster/prevención & control , Programas de Inmunización/economía , Adolescente , Adulto , Anciano , Varicela/economía , Varicela/epidemiología , Varicela/transmisión , Vacuna contra la Varicela/economía , Niño , Preescolar , Análisis Costo-Beneficio , Herpes Zóster/economía , Herpes Zóster/epidemiología , Herpes Zóster/transmisión , Vacuna contra el Herpes Zóster/economía , Herpesvirus Humano 3/inmunología , Herpesvirus Humano 3/patogenicidad , Humanos , Programas de Inmunización/métodos , Programas de Inmunización/estadística & datos numéricos , Incidencia , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Modelos Biológicos , Modelos Económicos , Años de Vida Ajustados por Calidad de Vida , Suecia/epidemiología , Resultado del Tratamiento , Activación Viral , Adulto JovenRESUMEN
INTRODUCTION: Children may receive measles-mumps-rubella (MMR) and varicella (VAR) vaccines separately or as measles-mumps-rubella-varicella (MMRV). We examined whether pediatric herpes zoster (HZ) incidence varied by pattern of varicella vaccine administration. METHODS: In six integrated health systems, we examined HZ incidence among children turning 12 months old during 2003-2008. All received varicella and MMR vaccines on recommended schedules. Cases were identified through 2014 using ICD-9 codes. Incidence was examined by number of varicella vaccine doses and same-day MMR. RESULTS: Among 199,797 children, overall HZ incidence was 18.6/100,000 person-years in the first-dose MMR + VAR group, 17.9/100,000 person-years in the MMRV group, and 7.5/100,000 person-years in the VAR-alone group. HZ incidence was lower following the second dose than before the second dose in all first-dose groups. CONCLUSIONS: HZ incidence was not meaningfully different between the MMRV and MMR + VAR first-dose groups. Overall and within first-dose groups, HZ incidence was lower among children receiving two varicella vaccine doses.
Asunto(s)
Varicela , Herpes Zóster , Sarampión , Paperas , Anticuerpos Antivirales , Varicela/epidemiología , Varicela/prevención & control , Vacuna contra la Varicela , Herpes Zóster/epidemiología , Herpes Zóster/prevención & control , Humanos , Incidencia , Lactante , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas/epidemiología , Paperas/prevención & control , Vacunas CombinadasRESUMEN
OBJECTIVES: The aim of the study was to evaluate the following: i) number of midwives and nurses at risk for contracting varicella; ii) effectiveness of infectious disease prevention among healthcare personnel; iii) attitude of healthcare person-nel towards immunization. MATERIAL AND METHODS: A total of 524 midwives and nurses from obstetric, neonatal, and pediatric wards were investigated. Quantitative data analysis was performed. RESULTS: Overall, 14.7% potentially seronegative respondents were identified. Out of those with a positive history of varicella, 6.56% contracted the disease after starting work, and > 70% had contact with the varicella-zoster virus. Overall, 9.54% of the respondents had a history of varicella, 3.12% were informed about the possibility of immunization, and 1.56% of those with a negative history of the disease were offered a state-funded vaccine. In the same group, the number of vaccinated people amounted to 13.28%, and 26.13% would accept a state-funded vaccine. CONCLUSIONS: Varicella may constitute a significant threat to maternal and fetal health at obstetric, neonatal, and pediatric wards, which must be considered when providing care to women in the reproductive age. Occupational health physicians should confirm the immunity status of the patients and suggest immunization to seronegative subjects. Regular workshops are necessary to update the knowledge of medical professionals and patients in order to shape their attitudes and beliefs about immunization.
Asunto(s)
Varicela/epidemiología , Transmisión de Enfermedad Infecciosa de Profesional a Paciente/prevención & control , Partería/estadística & datos numéricos , Enfermeras y Enfermeros/estadística & datos numéricos , Complicaciones Infecciosas del Embarazo/prevención & control , Adulto , Actitud del Personal de Salud , Varicela/inmunología , Varicela/prevención & control , Varicela/transmisión , Vacuna contra la Varicela/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polonia/epidemiología , Embarazo , Estudios Seroepidemiológicos , Vacunación , Adulto JovenRESUMEN
BACKGROUND: Varicella is a highly infectious disease with a significant public health and economic burden, which can be prevented with childhood routine varicella vaccination. Vaccination strategies differ by country. Some factors are known to play an important role (number of doses, coverage, dosing interval, efficacy and catch-up programmes), however, their relative impact on the reduction of varicella in the population remains unclear. This paper aims to help policy makers prioritise the critical factors to achieve the most successful vaccination programme with the available budget. METHODS: Scenarios assessed the impact of different vaccination strategies on reduction of varicella disease in the population. A dynamic transmission model was used and adapted to fit Italian demographics and population mixing patterns. Inputs included coverage, number of doses, dosing intervals, first-dose efficacy and availability of catch-up programmes, based on strategies currently used or likely to be used in different countries. The time horizon was 30 years. RESULTS: Both one- and two-dose routine varicella vaccination strategies prevented a comparable number of varicella cases with complications, but two-doses provided broader protection due to prevention of a higher number of milder varicella cases. A catch-up programme in susceptible adolescents aged 10-14 years old reduced varicella cases by 27-43 % in older children, which are often more severe than in younger children. Coverage, for all strategies, sustained at high levels achieved the largest reduction in varicella. In general, a 20 % increase in coverage resulted in a further 27-31 % reduction in varicella cases. When high coverage is reached, the impact of dosing interval and first-dose vaccine efficacy had a relatively lower impact on disease prevention in the population. Compared to the long (11 years) dosing interval, the short (5 months) and medium (5 years) interval schedules reduced varicella cases by a further 5-13 % and 2-5 %, respectively. Similarly, a 10 % increase in first-dose efficacy (from 65 to 75 % efficacy) prevented 2-5 % more varicella cases, suggesting it is the least influential factor when considering routine varicella vaccination. CONCLUSIONS: Vaccination strategies can be implemented differently in each country depending on their needs, infrastructure and healthcare budget. However, ensuring high coverage remains the critical success factor for significant prevention of varicella when introducing varicella vaccination in the national immunisation programme.
Asunto(s)
Vacuna contra la Varicela/economía , Varicela/economía , Varicela/prevención & control , Programas de Inmunización/economía , Vacunación Masiva/economía , Adolescente , Presupuestos , Varicela/epidemiología , Vacuna contra la Varicela/administración & dosificación , Vacuna contra la Varicela/uso terapéutico , Niño , Femenino , Humanos , Italia/epidemiología , Masculino , Modelos Teóricos , Programas Nacionales de Salud/economía , Vacunación/economía , Vacunas Atenuadas/uso terapéuticoRESUMEN
Patients with inflammatory bowel disease (IBD) do not receive routine preventative care at the same rate as general medical patients. This patient population is at increased risk of vaccine preventable illness such as influenza and pneumococcal pneumonia. This review will discuss health maintenance needs and preventative care issues in patients with IBD.
Asunto(s)
Neoplasias Colorrectales/diagnóstico , Inmunosupresores/efectos adversos , Enfermedades Inflamatorias del Intestino/terapia , Medicina Preventiva/métodos , Vacunación/métodos , Conservadores de la Densidad Ósea/uso terapéutico , Varicela/etiología , Varicela/inmunología , Varicela/prevención & control , Vacuna contra la Varicela/uso terapéutico , Depresión/diagnóstico , Depresión/terapia , Manejo de la Enfermedad , Detección Precoz del Cáncer/métodos , Hepatitis Viral Humana/etiología , Hepatitis Viral Humana/inmunología , Hepatitis Viral Humana/prevención & control , Herpes Zóster/etiología , Herpes Zóster/inmunología , Herpes Zóster/prevención & control , Vacuna contra el Herpes Zóster/uso terapéutico , Humanos , Huésped Inmunocomprometido , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/etiología , Gripe Humana/inmunología , Gripe Humana/prevención & control , Sarampión/etiología , Sarampión/inmunología , Sarampión/prevención & control , Vacuna contra el Sarampión-Parotiditis-Rubéola/uso terapéutico , Meningitis Meningocócica/etiología , Meningitis Meningocócica/inmunología , Meningitis Meningocócica/prevención & control , Vacunas Meningococicas/uso terapéutico , Paperas/etiología , Paperas/inmunología , Paperas/prevención & control , Osteoporosis/diagnóstico por imagen , Osteoporosis/tratamiento farmacológico , Infecciones por Papillomavirus/etiología , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/uso terapéutico , Vacunas Neumococicas/uso terapéutico , Neumonía Neumocócica/etiología , Neumonía Neumocócica/inmunología , Neumonía Neumocócica/prevención & control , Rubéola (Sarampión Alemán)/etiología , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/prevención & control , Cese del Hábito de Fumar , Vacunas contra Hepatitis Viral/uso terapéutico , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/diagnósticoRESUMEN
OBJECTIVE: To evaluate the long-term safety and efficacy of varicella vaccination in children with juvenile idiopathic arthritis (JIA) treated with biologics. METHODS: We performed a prospective study with long term follow up. Six patients with JIA treated with biologics, received 2 doses of varicella vaccine. Before vaccination, JIA was stable on therapy and peripheral blood lymphocyte populations were within normal limits. After vaccination, children were followed for disease activity, infections and production of protective antibodies. RESULTS: There were no serious side effects after vaccination and no varicella infection. Disease activity remained stable. Five patients (83%) produced protective antibodies against varicella virus 6 weeks after the second vaccination. One patient with low level of protective antibodies got mild varicella infection 4 months after the second vaccination. CONCLUSION: Varicella vaccination appears to be safe in our group of six JIA patients treated with biologics. Vaccination does not always protect against varicella infection.
Asunto(s)
Anticuerpos Antivirales/sangre , Artritis Juvenil/inmunología , Artritis Juvenil/patología , Terapia Biológica/métodos , Vacuna contra la Varicela/efectos adversos , Vacuna contra la Varicela/inmunología , Varicela/prevención & control , Artritis Juvenil/terapia , Vacuna contra la Varicela/administración & dosificación , Niño , Preescolar , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/patología , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Adverse pregnancy outcomes (APOs) can be increased by preconception risk factors and lifestyles.We measured the prevalence of preconception risk factors for APOs in a population of Italian women of childbearing age enrolled in a web-based study. METHODS: Participants were enrolled through a web platform (http://www.mammainforma.it). After enrollment, participants filled in a questionnaire regarding socio-demographic characteristics, clinical data and preconception risk factors for adverse pregnancy outcomes. Through logistic regression, we explored how the prevalence of risk factors was affected by age, education level, employment, parity, physician's recommendation and knowledge of the specific risk factor. RESULTS: We enrolled a total of 728 women. Sixty-two percent had a University degree, 84% were employed and 77% were planning their first pregnancy.Nearly 70% drank alcohol in any quantity; 16% were smokers; 6% was underweight; 21.4% was overweight; 51.6% did not assume folic acid; 22% was susceptible to rubella, 44.5% to hepatitis b and 13.2% to varicella.According to the multivariate analysis, compared to women who already had at least one pregnancy, nulliparous women had a higher BMI [OR 1.60 (CI 1.02;2.48)] and were less likely to be susceptible to rubella [OR 0.33 (CI 0.20;0.58)] and to be consuming alcohol [OR 0.47 (CI 0.31;0.70)] or cigarettes [OR 0.48 (CI 0.26;0.90)].Appropriate knowledge was associated with a correct behavior regarding smoking, drinking alcohol and folic acid supplementation. CONCLUSIONS: This study shows that the prevalence of risk factors for APOs in our population is high.Interventions aimed at reducing risk factors for APOs are needed and, to this purpose, a web intervention may represent a feasible tool to integrate tailored information and to inform preconception counseling targeting a specific group of women planning a pregnancy who are engaged on the web.
Asunto(s)
Consumo de Bebidas Alcohólicas/epidemiología , Conocimientos, Actitudes y Práctica en Salud , Sobrepeso/epidemiología , Atención Preconceptiva/estadística & datos numéricos , Fumar/epidemiología , Delgadez/epidemiología , Vacunación/estadística & datos numéricos , Adulto , Índice de Masa Corporal , Varicela/prevención & control , Suplementos Dietéticos , Femenino , Ácido Fólico/administración & dosificación , Conductas Relacionadas con la Salud , Hepatitis B/prevención & control , Humanos , Internet , Italia , Paridad , Embarazo , Prevalencia , Factores de Riesgo , Rubéola (Sarampión Alemán)/prevención & control , Encuestas y Cuestionarios , Complejo Vitamínico B/administración & dosificaciónAsunto(s)
Vacunación Masiva , Adulto , Varicela/prevención & control , Niño , Servicios de Salud del Niño/organización & administración , Cólera/prevención & control , Prestación Integrada de Atención de Salud , Femenino , Hepatitis A/prevención & control , Herpes Zóster/prevención & control , Humanos , Lactante , Infecciones por Papillomavirus/prevención & control , Poliomielitis/prevención & control , Embarazo , Vacunas/efectos adversos , Vacunas/economía , Vacunas/provisión & distribución , Tos Ferina/prevención & control , Organización Mundial de la Salud , Fiebre Amarilla/prevención & controlRESUMEN
Both conventional virus vaccines and those being introduced in the near future are either live attenuated viruses or nonliving inactivated viruses, mere virus-like particles (VLP) or purified proteins. Live vaccines yield a "more natural" immunity, but in many cases also a nonliving vaccine is sufficient to protect from viral infections. Influenza vaccines are of both types. The commencing HPV vaccination program will be conducted with a VLP vaccine comprising two serotypes. A live chickenpox vaccine will be introduced in the national vaccination program in the next few years. In addition, a shingles vaccine is needed. The live oral rotavirus vaccine works well.
Asunto(s)
Vacunas Virales/inmunología , Varicela/inmunología , Varicela/prevención & control , Finlandia , Herpes Zóster/inmunología , Herpes Zóster/prevención & control , Humanos , Gripe Humana/inmunología , Gripe Humana/prevención & control , Programas Nacionales de Salud , Infecciones por Papillomavirus/inmunología , Infecciones por Papillomavirus/prevención & control , Infecciones por Rotavirus/inmunología , Infecciones por Rotavirus/prevención & controlRESUMEN
OBJECTIVE: To evaluate the safety and epidemiological effect of the Freeze-dried Live attenuated varicella vaccine. METHODS: A random, double-blind control clinical trial was adopted. RESULTS: In the observation period, the incidence of varicella was 0.8 per thousand in the experimental group and 8.7 per thousand in control group. There was a significant difference (B.P=0.000017). Vaccine effectiveness (VE(%)) was 90.8%, the lower limit of 95%CI was 88.7%. CONCLUSION: The varicella vaccine produced by Changchun keygen biological products co., Ltd. was safe and effective.
Asunto(s)
Vacuna contra la Varicela/administración & dosificación , Varicela/epidemiología , Varicela/prevención & control , Varicela/inmunología , Vacuna contra la Varicela/inmunología , Niño , Preescolar , China/epidemiología , Evaluación Preclínica de Medicamentos , Femenino , Liofilización , Humanos , Masculino , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/inmunologíaRESUMEN
An economic evaluation of universal varicella vaccination in Italy was performed to assess the potential clinical and economic effects of three different strategies versus no vaccination. By means of the EVITA model, vaccination with two doses in toddlers only (1-1.5 years), adolescents only (13 years) and toddlers with adolescents catch-up programmes were simulated. All universal varicella vaccination strategies including toddlers (with or without an adolescent catch-up programme) turned out to be highly effective in reducing the burden of disease due to varicella. In addition, they lead to significant net savings from the societal perspective but to higher costs compared to return of investment from National Health Service perspective. The huge economic burden of hospitalised uncomplicated varicella cases registered in Italy can partially explain these highly beneficial findings for the societal perspective. Overall, our analysis confirmed the favourable clinical and economic impact of routine varicella vaccination with two doses of vaccine in Italy.
Asunto(s)
Vacuna contra la Varicela/administración & dosificación , Vacuna contra la Varicela/economía , Vacunación/economía , Adolescente , Adulto , Varicela/economía , Varicela/epidemiología , Varicela/prevención & control , Niño , Preescolar , Análisis Costo-Beneficio , Herpesvirus Humano 3 , Hospitalización , Humanos , Programas de Inmunización/economía , Esquemas de Inmunización , Lactante , Italia/epidemiología , Modelos Económicos , Programas Nacionales de Salud/economíaAsunto(s)
Vacunación Masiva , Canadá , Varicela/prevención & control , Humanos , Gripe Humana/prevención & control , Infecciones Meningocócicas/prevención & control , Programas Nacionales de Salud , Infecciones Neumocócicas/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Tos Ferina/prevención & controlRESUMEN
BACKGROUND: Varicella vaccine was licensed in Canada in 1998. The province of Alberta introduced a universal publicly funded varicella vaccination program in 2001. PURPOSE: To describe the epidemiology of non-fatal cases of chickenpox for which publicly funded health services were utilized for the period 1986-2002. METHODS: We used the records of Alberta's universal, publicly funded health care insurance system to identify cases of chickenpox for the period 1986-2002. The earliest dated utilization of a health service for which there was an ICD9-CM code of 052.xx or an IC10-CA code of B01.xx was used as the date of illness onset. Denominators for rates were estimated using mid-year population estimates from the Alberta Health Care Insurance Registry. Age-specific rates were estimated for each year. RESULTS: The crude incidence of chickenpox significantly declined over the period 1994-2002, most steeply after the year 2000. The incidence of chickenpox varied by age group and year and there was evidence of age-group-year interaction. Among those aged 5-19 years, chickenpox incidence began to decline prior to vaccine licensure in Canada. Among those aged less than one year and those aged 1-4 years, the incidence increased until 1999 when a decline began. Over the period 0.8% of cases were hospitalized. CONCLUSION: Chickenpox rates began to decline prior to the introduction of the publicly funded vaccination program; however the declines in rates among the youngest age-groups are consistent with a vaccination program effect.
Asunto(s)
Varicela/epidemiología , Adolescente , Adulto , Factores de Edad , Anciano , Alberta/epidemiología , Varicela/prevención & control , Vacuna contra la Varicela , Niño , Preescolar , Interpretación Estadística de Datos , Bases de Datos Factuales , Atención a la Salud/economía , Femenino , Hospitalización , Humanos , Lactante , Masculino , Vacunación Masiva/legislación & jurisprudencia , Vacunación Masiva/tendencias , Persona de Mediana Edad , Programas Nacionales de Salud , Estaciones del Año , Factores SexualesRESUMEN
OBJECTIVE: To determine the economic impact of childhood varicella vaccination in France and Germany. METHODS: A common methodology based on the use of a varicella transmission model was used for the two countries. Cost data (2002 per thousand) were derived from two previous studies. The analysis focused on a routine vaccination program for which three different coverage rates (CRs) were considered (90%, 70%, and 45%). Catch-up strategies were also analyzed. A societal perspective including both direct and indirect costs and a third-party payer perspective were considered (Social Security in France and Sickness Funds in Germany). RESULTS: A routine vaccination program has a clear positive impact on varicella-related morbidity in both countries. With a 90% CR, the number of varicella-related deaths was reduced by 87% in Germany and by 84% in France. In addition, with a CR of 90%, routine varicella vaccination induces savings in both countries from both societal (Germany 61%, France 60%) and third-party payer perspectives (Germany 51%, France 6.7%). For lower CRs, routine vaccination remains cost saving from a third-party payer perspective in Germany but not in France, where it is nevertheless cost-effective (cost per life-year gained of 6521 per thousand in the base case with a 45% CR). CONCLUSION: Considering the impact of vaccination on varicella morbidity and costs, a routine varicella vaccination program appears to be cost saving in Germany and France from both a societal and a third-party payer perspective. For France, routine varicella vaccination remains cost-effective in worst cases when a third-party payer perspective is adopted. Catch-up programs provide additional savings.
Asunto(s)
Vacuna contra la Varicela/economía , Varicela/economía , Varicela/prevención & control , Ahorro de Costo/estadística & datos numéricos , Costos de la Atención en Salud/estadística & datos numéricos , Programas de Inmunización/economía , Distribución por Edad , Varicela/epidemiología , Varicela/transmisión , Vacuna contra la Varicela/inmunología , Niño , Preescolar , Costo de Enfermedad , Análisis Costo-Beneficio , Femenino , Francia/epidemiología , Alemania/epidemiología , Costos de la Atención en Salud/clasificación , Humanos , Programas de Inmunización/estadística & datos numéricos , Lactante , Reembolso de Seguro de Salud/estadística & datos numéricos , Masculino , Modelos Econométricos , Programas Nacionales de Salud/economía , Evaluación de Programas y Proyectos de SaludRESUMEN
Varicella vaccine has been licensed in Canada since December 1998 but not provided free in all provinces. Through a cross-sectional telephone survey to a random sample of parents, we assessed factors associated with varicella vaccine uptake in the absence of public funding. Parents of children aged 2-3 years (Group I) and 6-7 years (Group II) were contacted between March and May 2003 in British Columbia, Canada. Response rate was 82% (Group I=571; Group II=704). Among susceptible children, varicella vaccine coverage was 21% (95% CI 18-25%) and 28% (95% CI 22-33%), respectively. There were significant disparities in vaccine coverage based on income and residence. Physician or nurse recommendation was a strong determinant of vaccine uptake as were belief in the safety and efficacy of vaccine. Among parents of susceptible children, 59% (343/582) would vaccinate their child if it were provided free; 25% (148/582) were undecided.
Asunto(s)
Vacuna contra la Varicela/economía , Varicela/economía , Programas de Inmunización/economía , Colombia Británica , Varicela/prevención & control , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Masculino , Programas Nacionales de Salud/economíaRESUMEN
Varicella zoster virus (VZV) causes both chickenpox and herpes zoster and is responsible for a significant disease burden, including hospitalizations and deaths, in Australian children and adults. Varicella vaccine has been available in Australia for 5 years; however, from November 2005, it will be funded for use in all susceptible children at 18 months and 10-13 years of age under the National Immunisation Program. Experience with universal varicella vaccination of children in the USA over the last 10 years has shown that the vaccine is safe and highly effective in reducing varicella-related disease. This review summarizes the epidemiology of VZV-related disease in Australia, the use of varicella vaccine and the international experience with vaccine efficacy and safety. The potential impact of varicella vaccination on the incidence of herpes zoster is also discussed.
Asunto(s)
Vacuna contra la Varicela , Programas de Inmunización , Adolescente , Australia , Varicela/prevención & control , Vacuna contra la Varicela/economía , Vacuna contra la Varicela/uso terapéutico , Niño , Contraindicaciones , Análisis Costo-Beneficio , Herpes Zóster/prevención & control , Humanos , Incidencia , Lactante , Programas Nacionales de Salud/economía , Seguridad , Resultado del TratamientoRESUMEN
AIM: To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. METHODS: This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Euro, 2002 values) were collected through a literature review. Several vaccination scenarios were analysed: (i) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) without any catch-up programme; (ii) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) completed by a catch-up programme for 6-year-old children over the first 5 years of vaccine marketing; and (iii) routine vaccination programme for children aged 1-2 years with different levels of vaccination coverage (90%, 70% and 45%) completed by a catch-up programme during the first year of vaccine marketing for children aged 2-11 years. PERSPECTIVES: A societal perspective, including both direct and indirect costs, and a health-system perspective, limited to costs supported by Italian Health Authorities, were considered. RESULTS: A routine vaccination programme has a clearly positive impact on chickenpox morbidity. Respectively, 68% and 57% of chickenpox-related hospitalisations and deaths could be prevented with a 90% coverage rate. With vaccination costs being more than offset by a reduction in chickenpox treatment costs in the base case, such a programme could also induce savings from both a societal and a health-system perspective (40% and 12% savings, respectively for a 90% coverage rate). A lower coverage rate reduces cost savings, but there is still a 9% decrease in overall societal costs for a 45% coverage rate. Although the reduction in total societal costs was robust to the sensitivity analyses performed, a slight uncertainty remains regarding cost reduction from a health-system perspective. However, in this latter perspective, even in the worst-case scenario of the sensitivity analysis, routine vaccination programmes may be cost effective, the worst-case scenario for cost parameters leading to cost per life-year gained of Euro2853. Catch-up programmes combined with routine vaccination should lead to further cost reductions from a societal perspective: 15% for a massive catch-up during the first year of vaccine marketing compared with toddlers' vaccination alone, and 11% for a catch-up focused on 6-year-old children for a period of 5 years. However, the impact of catch-up programmes on the costs from an Italian health-system perspective remains close to zero (+/-1%). CONCLUSION: This model suggests, with its underlying assumptions and data, that routine ZVZ vaccination may be cost saving from both a societal and a health system perspective in the base case. In the worst-case scenario of the sensitivity analysis, vaccination remains cost effective.